Analyst Price Targets — BMRN
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 7, 2026 11:28 am | Luca Issi | RBC Capital | $62.00 | $58.79 | TheFly | BioMarin price target lowered to $62 from $66 at RBC Capital |
| May 22, 2026 10:39 am | — | Canaccord Genuity | $111.00 | $54.10 | TheFly | BioMarin price target lowered to $111 from $116 at Canaccord |
| May 18, 2026 6:47 pm | — | Leerink Partners | $62.00 | $49.67 | TheFly | BioMarin price target lowered to $62 from $64 at Leerink |
| May 18, 2026 2:17 pm | — | H.C. Wainwright | $50.00 | $50.15 | TheFly | BioMarin price target lowered to $50 from $55 at H.C. Wainwright |
| May 11, 2026 9:08 am | — | Goldman Sachs | $69.00 | $54.06 | TheFly | BioMarin reinstated with a Neutral at Goldman Sachs |
| May 5, 2026 12:09 pm | — | Evercore ISI | $120.00 | $54.36 | TheFly | BioMarin price target raised to $120 from $110 at Evercore ISI |
| May 5, 2026 10:44 am | William Pickering | Tudor Pickering | $82.00 | $55.46 | TheFly | BioMarin price target lowered to $82 from $94 at Bernstein |
| April 27, 2026 10:16 am | Sean Laaman | Morgan Stanley | $120.00 | $53.18 | TheFly | BioMarin resumed with an Overweight at Morgan Stanley |
| March 12, 2026 1:26 pm | Akash Tewari | Jefferies | $103.00 | $59.86 | StreetInsider | Jefferies Reiterates Buy Rating on BioMarin Pharmaceutical Inc. (BMRN): "data looks viable and is a positive sign" |
| March 3, 2026 11:12 am | Eliana Merle | Barclays | $105.00 | $59.74 | StreetInsider | BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $105 at Barclays |
Latest News for BMRN
BioMarin's FDA filing for full Voxzogo approval in achondroplasia has been accepted, with a regulatory decision expected by Feb. 28, 2027.
Application based on long-term safety and efficacy data from three ongoing studies, including adult height and additional clinical outcomes beyond linear growth, including body proportionality and arm span evaluated over long-term follow-up FDA PDUFA target action date of Feb. 28, 2027 SAN RAFAEL, Calif., July 13, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the U.S. Food and…
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Data from an investigator-led study showed treatment with VOXZOGO resulted in sustained improvements in growth over three years in children with hypochondroplasia New Phase 1 results also presented for investigational BMN 333 support potential weekly dosing in children with achondroplasia SAN RAFAEL, Calif., June 16, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced new data from studies of…
BioMarin (BMRN) reported earnings 30 days ago. What's next for the stock?
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for BMRN.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.